摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-cyclohexyl-1-(4-methoxyphenyl)propan-1-one | 31480-67-8

中文名称
——
中文别名
——
英文名称
3-cyclohexyl-1-(4-methoxyphenyl)propan-1-one
英文别名
3-Cyclohexyl-1-(4-methoxy-phenyl)-propan-1-one
3-cyclohexyl-1-(4-methoxyphenyl)propan-1-one化学式
CAS
31480-67-8
化学式
C16H22O2
mdl
MFCD11545171
分子量
246.349
InChiKey
ROLNKJTZKCZLDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.562
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-cyclohexyl-1-(4-methoxyphenyl)propan-1-one吡啶盐酸盐 作用下, 生成 3-cyclohexyl-1-(4-hydroxy-phenyl)-propan-1-one
    参考文献:
    名称:
    Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs
    摘要:
    A series of 3-alkyl, 3-cycloalkyl, and 3-heteroaryl dihydrobenzoxathim analogs 1 were prepared and evaluated for estrogen/anti-estrogen activity in both in vitro and in vivo models. In general, the compounds were found to exhibit a high degree of selectivity for ERalpha over ERbeta, but were less potent than the original lead compound la in the inhibition of estradiol-driven uterine proliferation. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.02.084
  • 作为产物:
    描述:
    环己基-(4-甲氧基-苯基)-甲酮2,4,6-三甲基吡啶 、 Ir[dF(CF3)ppy]2(5,5'-dCF3bpy)PF6 作用下, 以 四氢呋喃 为溶剂, 反应 72.0h, 生成 3-cyclohexyl-1-(4-methoxyphenyl)propan-1-one
    参考文献:
    名称:
    通过质子耦合电子转移实现烯丙醇中的 1,3-烷基转位
    摘要:
    描述了一种通过 1,3-烷基转位将无环烯丙醇异构化为 β-官能化酮的方法。该反应通过光驱动的质子耦合电子转移 (PCET) 激活烯丙醇底物中的 O-H 键,随后产生的烷氧基自由基的 C-C β-断裂来进行。在断裂事件中产生的瞬态烷基自由基和烯酮受体随后通过自由基共轭加成重组以提供 β-官能化酮产物。多种带有烷基和酰基迁移基团的烯丙醇底物被成功地调节。来自机理研究的见解导致改进的反应方案提高了对具有挑战性的底物的反应性能。
    DOI:
    10.1002/anie.202105285
点击查看最新优质反应信息

文献信息

  • Scope and Mechanism of the Redox-Active 1,2-Benzoquinone Enabled Ruthenium-Catalyzed Deaminative α-Alkylation of Ketones with Amines
    作者:Pandula T. Kirinde Arachchige、Suhashini Handunneththige、Marat R. Talipov、Nishantha Kalutharage、Chae S. Yi
    DOI:10.1021/acscatal.1c04732
    日期:2021.11.19
    mediate a regioselective deaminative coupling reaction of ketones with amines to form the α-alkylated ketone products. Both benzylic and aliphatic primary amines were found to be suitable substrates for the coupling reaction with ketones in forming the α-alkylated ketone products. The coupling reaction of PhCOCD3 with 4-methoxybenzylamine showed an extensive H/D exchange on both α-CH2 (41% D) and β-CH2
    发现由阳离子 Ru-H 配合物与 3,4,5,6-四氯-1,2-苯醌反应原位形成的催化体系介导酮与胺的区域选择性脱氨基偶联反应,形成α-烷基化酮产品。发现苄基和脂肪族伯胺都是与酮偶联反应形成α-烷基化酮产物的合适底物。PhCOCD 3与4-甲氧基苄胺的偶联反应在烷基化产物的α-CH 2 (41% D)和β-CH 2 (21%)位置上显示出广泛的H/D交换。从苯乙酮与对位取代苄胺p- XC反应获得的哈米特图6 H 4 CH 2 NH 2 (X = OMe, Me, H, F, Cl, CF 3 ) 显示出具有电子释放基团的胺底物的强烈促进作用 (ρ = -0.49 ± 0.1)。在苯乙酮与 4-甲氧基苄胺偶联反应的烷基化产物 ( C α = 1.020)的 α-碳上观察到最显着的碳同位素效应。来自分离的亚胺底物的烷基化反应动力学导致经验速率定律:速率 = k [Ru][亚胺]。通过阳离子 Ru-H
  • Ni-Catalyzed β-Alkylation of Cyclopropanol-Derived Homoenolates
    作者:L. Reginald Mills、Cuihan Zhou、Emily Fung、Sophie A. L. Rousseaux
    DOI:10.1021/acs.orglett.9b03435
    日期:2019.11.1
    Metal homoenolates are valuable synthetic intermediates which provide access to β-functionalized ketones. In this report, we disclose a Ni-catalyzed β-alkylation reaction of cyclopropanol-derived homoenolates using redox-active N-hydroxyphthalimide (NHPI) esters as the alkylating reagents. The reaction is compatible with 1°, 2°, and 3° NHPI esters. Mechanistic studies imply radical activation of the
    金属均烯酸酯是有价值的合成中间体,可提供获得β-官能化酮的途径。在此报告中,我们公开了使用氧化还原活性N-羟基邻苯二甲酰亚胺(NHPI)酯作为烷基化试剂的镍催化的环丙醇衍生的均烯酸酯的β-烷基化反应。该反应与1°,2°和3°NHPI酯相容。机理研究表明,在环丙醇上会发生NHPI酯的自由基活化和2eβ-碳的消除。
  • TRISUBSTITUTED THIAZOLE COMPOUNDS, PREPARATIONS METHODS, PHARMACEUTICAL COMPOSITIONS AND MEDICALS USES THEREOF
    申请人:Li Song
    公开号:US20090298832A1
    公开(公告)日:2009-12-03
    The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.
    本发明涉及公式(I)的2,4,5-三取代噻唑化合物或所有可能的异构体、前药、药用盐、溶剂合物或水合物,用于抑制血浆PLTP活性和/或血浆CETP活性,其中取代基如规范中定义;一种用于制备公式(I)化合物的方法;包括公式(I)化合物的药物组合物以及其用于制备治疗和/或预防与哺乳动物体内增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途,如动脉粥样硬化、心血管疾病和周围血管疾病等。
  • Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof
    申请人:Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.C. China
    公开号:US08053581B2
    公开(公告)日:2011-11-08
    The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the compounds of formula (I); a pharmaceutical composition comprising the compound of formula (I) and its use for the preparation of a medicament for treatment and/or prevention of diseases associated with the increased plasma PLTP activity and/or the increased plasma CETP activity in a mammal, such as atherosclerosis, cardiovascular diseases and peripheral vascular diseases, etc.
    本发明涉及公式(I)的2,4,5-三取代噻唑化合物或其所有可能的异构体、前药、药学上可接受的盐、溶剂化合物或水合物,用于抑制血浆PLTP活性和/或血浆CETP活性,其中取代基如规范中所定义;一种制备公式(I)化合物的方法;包括公式(I)化合物的制药组合物以及其用于制备哺乳动物(如动脉粥样硬化、心血管疾病和周围血管疾病等)的治疗和/或预防与增加的血浆PLTP活性和/或增加的血浆CETP活性相关的疾病的药物的用途。
  • Nickel-Catalyzed Deaminative Alkyl–Alkyl Cross-Coupling of Katritzky Salts with Cyclopropanols: Merging C–N and C–C Bond Activation
    作者:Xingjie Zhang、Shilin Cui、Shuxin Wei、Mengge Zhao、Xiaopan Liu、Guisheng Zhang
    DOI:10.1021/acs.orglett.4c00424
    日期:2024.3.15
    practical nickel-catalyzed deaminative alkylation of Katritzky salts with cyclopropyl alcohols via merging C–N and C–C bond activation. This protocol enables the formation of an alkyl–alkyl bond along with the generation of a versatile ketone functional group in a single operation, thus providing a convenient approach for accessing β-alkyl ketones. This reaction is distinguished by its high functional
    在此,我们报告了一种通用且实用的镍催化卡特里茨基盐与环丙醇通过合并 C-N 和 C-C 键活化的脱氨烷基化反应。该方案能够在一次操作中形成烷基-烷基键并生成多功能酮官能团,从而为获取 β-烷基酮提供了一种便捷的方法。该反应的特点是具有高官能团耐受性、广泛的底物范围以及复杂生物活性分子的高效后期衍生化。
查看更多